258 related articles for article (PubMed ID: 30941350)
21. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
[TBL] [Abstract][Full Text] [Related]
22. Treatment of rheumatoid arthritis: Unraveling the conundrum.
Zampeli E; Vlachoyiannopoulos PG; Tzioufas AG
J Autoimmun; 2015 Dec; 65():1-18. PubMed ID: 26515757
[TBL] [Abstract][Full Text] [Related]
23. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study.
Huang Y; Agarwal SK; Chen H; Chatterjee S; Johnson ML; Aparasu RR
Clin Ther; 2023 Sep; 45(9):e177-e186. PubMed ID: 37573225
[TBL] [Abstract][Full Text] [Related]
24. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
Nakayamada S; Kubo S; Iwata S; Tanaka Y
BioDrugs; 2016 Oct; 30(5):407-419. PubMed ID: 27577235
[TBL] [Abstract][Full Text] [Related]
25. Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Bhushan V; Lester S; Briggs L; Hijjawi R; Shanahan EM; Pontifex E; Ninan J; Hill C; Cai F; Walker J; Goldblatt F; Wechalekar MD
Front Med (Lausanne); 2021; 8():708168. PubMed ID: 34646840
[No Abstract] [Full Text] [Related]
26. Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry.
Jung JY; Lee E; Kim JW; Suh CH; Kim HA
Clin Exp Rheumatol; 2023 May; 41(5):1034-1041. PubMed ID: 36062753
[TBL] [Abstract][Full Text] [Related]
27. DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis.
Wang SS; Lewis MJ; Pitzalis C
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509625
[TBL] [Abstract][Full Text] [Related]
28. Synovial tissue response to treatment in psoriatic arthritis.
Codullo V; McInnes IB
Open Rheumatol J; 2011; 5():133-7. PubMed ID: 22279513
[TBL] [Abstract][Full Text] [Related]
29. Kinesin-like protein CENP-E is upregulated in rheumatoid synovial fibroblasts.
Kullmann F; Judex M; Ballhorn W; Jüsten HP; Wessinghage D; Welsh J; Yen TJ; Lang B; Hittle JC; McClelland M; Gay S; Schölmerich J; Müller-Ladner U
Arthritis Res; 1999; 1(1):71-80. PubMed ID: 11056662
[TBL] [Abstract][Full Text] [Related]
30. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Smolen JS; Landewé R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg JE; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poór G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
Ann Rheum Dis; 2017 Jun; 76(6):960-977. PubMed ID: 28264816
[TBL] [Abstract][Full Text] [Related]
31. Network analysis of synovial RNA sequencing identifies gene-gene interactions predictive of response in rheumatoid arthritis.
Sciacca E; Surace AEA; Alaimo S; Pulvirenti A; Rivellese F; Goldmann K; Ferro A; Latora V; Pitzalis C; Lewis MJ
Arthritis Res Ther; 2022 Jul; 24(1):166. PubMed ID: 35820911
[TBL] [Abstract][Full Text] [Related]
32. JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data.
Harrington R; Al Nokhatha SA; Conway R
J Inflamm Res; 2020; 13():519-531. PubMed ID: 32982367
[TBL] [Abstract][Full Text] [Related]
33. The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: A systematic review and meta-analysis.
Vassilopoulos A; Shehadeh F; Benitez G; Kalligeros M; Cunha JS; Cunha CB; Mylonakis E
Front Pharmacol; 2022; 13():992713. PubMed ID: 36278224
[No Abstract] [Full Text] [Related]
34. The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis.
Alten R; Burmester GR; Matucci-Cerinic M; Salmon JH; Lopez-Romero P; Fakhouri W; de la Torre I; Zaremba-Pechmann L; Holzkämper T; Fautrel B
Rheumatol Ther; 2023 Feb; 10(1):73-93. PubMed ID: 36227530
[TBL] [Abstract][Full Text] [Related]
35. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
36. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs.
Tanaka Y
Rheumatology (Oxford); 2021 Dec; 60(Suppl 6):vi12-vi20. PubMed ID: 34951925
[TBL] [Abstract][Full Text] [Related]
37. Therapy with Biologic Agents After Diagnosis of Solid Malignancies: Results from the Corrona Registry.
Pappas DA; Rebello S; Liu M; Schenfeld J; Li Y; Collier DH; Accortt NA
J Rheumatol; 2019 Nov; 46(11):1438-1444. PubMed ID: 30936285
[TBL] [Abstract][Full Text] [Related]
38. 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Louthrenoo W; Kasitanon N; Katchamart W; Aiewruengsurat D; Chevaisrakul P; Chiowchanwisawakit P; Dechanuwong P; Hanvivadhanakul P; Mahakkanukrauh A; Manavathongchai S; Muangchan C; Narongroeknawin P; Phumethum V; Siripaitoon B; Suesuwan A; Suwannaroj S; Uea-Areewongsa P; Ukritchon S; Asavatanabodee P; Koolvisoot A; Nanagara R; Totemchokchyakarn K; Nuntirooj K; Kitumnuaypong T
Int J Rheum Dis; 2017 Sep; 20(9):1166-1184. PubMed ID: 28730640
[TBL] [Abstract][Full Text] [Related]
39. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]